Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Armstrong (Sheffield, United Kingdom), C. Billings (Sheffield, United Kingdom), S. Clayton (Sheffield, United Kingdom), J. Yorke (Manchester, United Kingdom), C. Harries (London, United Kingdom), D. Kiely (Sheffield, United Kingdom). Assessing the financial impact of pulmonary hypertension: a survey by the UK Pulmonary Hypertension Association (PHA-UK). 3085

Member's Comments

No comment yet.

Related content which might interest you: Portopulmonary hypertension in United Kingdom: A contemporary, national, observational study Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Impact of treatment strategy in survival of patients with idiopathic pulmonary arterial hypertension. Real world evidence from Spanish National Pulmonary Hypertension Registry (REHAP) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Examination about what determine quality of life (QOL) and the association between QOL and therapeutic intervention for patients with chronic thromboembolitic pulmonary hypertension (CTEPH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 A retrospective study of depressive illness in patients with pulmonary hypertension (PH) at a specialist centre Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Effects of pulmonary rehabilitation (PR) in idiopathic pulmonary arterial hypertension (PAHI) Source: Annual Congress 2013 –The latest insights in pulmonary rehabilitation (part 2) Year: 2013 The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2012; 39: 589-596 Year: 2012 Pulmonary arterial hypertension and general practitioners: Difficulties are mainly due to a lack of knowledge Source: Annual Congress 2013 –Improving educational programmes for patients and multidisciplinary healthcare professionals Year: 2013 Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 An evaluation of outcomes for patients with pulmonary hypertension (PH) incorporated into a standard UK pulmonary rehabilitation (PR) programme Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Single center experience with systematic diagnostic and predictive genetic screening for pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Risk categories from European guidelines applied to the French Pulmonary Hypertension (PH) registry Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Pulmonary rehabilitation in the United States: the American Association of Cardiovascular and Pulmonary Rehabilitation national pulmonary rehabilitation survey Source: International Congress 2014 – State of the nation(s) in terms of pulmonary rehabilitation: results from the Canadian, American and European pulmonary rehabilitation survey studies Year: 2014 Evaluation of a novel clinic for management of Chronic Thromboembolic Pulmonary Disease (CTED) and associated Pulmonary Hypertension (CTEPH). Source: International Congress 2017 – PAH and CTEPH Year: 2017 Pulmonary function is associated with pulmonary artery systolic pressure in the general population: The Rotterdam study Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals Source: Eur Respir Rev 2010 19: 272-278 Year: 2010 Long-term data from the Swiss pulmonary hypertension registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Pulmonary embolism in Spain: Differences between men and women Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015